Ankara T.C. Ministry of Health, Ankara, Turkey, Turkey (Türkiye) (Recruiting); Istanbul Universitesi faculty of Medicine, Istanbul, Turkey, Turkey (Türkiye) (Recruiting) - 25 Jul `25CGB-600 gel for facial vitiligo

CGB-600 gel for facial vitiligo

Official title: Safety and Effectiveness of CGB-600 Gel for the Treatment of Non-Segmental Facial Vitiligo: A Randomized, Double-Blind, Vehicle-Controlled Phase 1 Proof of Concept Study (Study No. CGB-600-02)

Status: Recruiting now

Description:

CAGE Bio Inc. plans to enroll about 36 participants. The experimental topical medicine is designed to reduce inflammation in vitiligo-affected skin. Researchers hope it will protect melanocytes and improve repigmentation. Possible effects may include redness, itching, burning, acne-like bumps, and infection; its full safety profile is still being studied. People ages 18 to 60 may qualify. The study is recruiting at 2 listed sites in Turkey (Türkiye).

Start date: July 25, 2025

Completion date: November 30, 2026

Organizer: CAGE Bio Inc.

Contact: Nitin Joshi, Ph.D.

Tel.: 650-996-1845

Email: njoshi@cagebio.com

Link: https://clinicaltrials.gov/study/NCT07357870

Clinical Trial Alerts

Sign up and be the first to know about updates on this trial.

This request will be sent with the trial reference CGB-600 gel for facial vitiligo . By submitting you agree to our Privacy Policy.

FAQOther Questions

  • Who is prone to vitiligo?

    Vitiligo can affect anyone, regardless of gender, age, or race. Vitiligo prevalence is between 0.76% and 1.11% of the U.S. population, including around 40% of those with the con...

  • What are rules for military service entry with vitiligo?

    Military service · Patient guide How do military-service rules for vitiligo differ across countries? There is no global standard. Every country writes its own entry rules, and m...

  • How smoking affects vitiligo?

    Smoking is a common habit linked to numerous health risks, affecting multiple body systems and increasing various disease risks, including respiratory and cardiovascular issues....